IP Library Granted Patent US 10,072,069
Granted Patent B2
US 10,072,069 · App. 15/206,063 · Granted Sep 11, 2018

Humanized monoclonal antibodies from a transgenic rat

Inventor: Roland Buelow (Palo Alto, CA)
C07K16/00A01K67/0276A01K67/0278C12N5/0609C12N9/22C12N15/8509A01K2207/15A01K2217/072A01K2217/075A01K2267/01C07K2317/14C07K2317/21C07K2317/24C07K2317/51C07K2317/76C12N2015/8518C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,072,069
App. No.
15/206,063
Granted
Sep 11, 2018
Kind
B2
Abstract

The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.

Claims (11)

1. A functional monoclonal antibody that specifically binds an immunogen and comprises a human immunoglobulin (Ig) variable region, wherein the functional monoclonal antibody is produced by a method comprising:

i) immunizing a transgenic rat with an immunogen, wherein the transgenic rat has a genome comprising:

a) a functionally ablated endogenous Ig heavy chain gene and/or a functionally ablated endogenous Ig light chain gene; and

b) a nucleic acid sequence encoding an exogenous human Ig variable region gene, wherein said rat is capable of producing a functional monoclonal antibody that specifically binds to the immunogen and comprises the human Ig variable region;

ii) isolating a nucleic acid sequence encoding the functional monoclonal antibody from B-cells of the immunized transgenic rat; and

iii) producing the functional monoclonal antibody from the nucleic acid sequence isolated in step ii).

2. The functional monoclonal antibody of claim 1 , wherein the functional monoclonal antibody has a rat constant (C) region or an artificial C region derived from human and rat C regions.

3. The functional monoclonal antibody of claim 2 , wherein the functional monoclonal antibody has an artificial C region derived from human and rat C regions comprising a human IgG CH1 domain and a rat IgG2 CH2 and CH3 domain.

4. The functional monoclonal antibody of claim 1 , wherein the exogenous human Ig variable gene is an Ig light and/or heavy chain gene.

5. The functional monoclonal antibody of claim 4 , wherein the transgenic rat has a genome further comprising a nucleic acid sequence encoding an exogenous human Ig diversity (D) region gene, wherein said rat is capable of producing a functional monoclonal antibody with the human variable and diversity regions that specifically binds to the immunogen.

6. The functional monoclonal antibody of claim 1 , wherein the exogenous human Ig variable region gene is a naturally occurring human Ig variable region gene.

Assignments (3)
CHANGE OF NAME Recorded Nov 16, 2022
From: OMNIAB, INC.
To: OMNIAB OPERATIONS, INC.
Reel/Frame 061952/0958 →
CHANGE OF NAME Recorded Mar 17, 2022
From: OPEN MONOCLONAL TECHNOLOGY, INC.
To: OMNIAB, INC.
Reel/Frame 059435/0056 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2017
From: BUELOW, PH.D., ROLAND
To: OPEN MONOCLONAL TECHNOLOGY, INC.
Reel/Frame 042666/0338 →
Continuity (5)
Continuation 13192407 · Jul 27, 2011
Division 12130818 · May 30, 2008
Provisional Application 61044324 · Apr 11, 2008
Provisional Application 60941619 · Jun 1, 2007
Related Publication 20160311888A1 · Oct 27, 2016